Abstract

Immunotherapy has emerged as a promising avenue for the treatment of breast cancer, offering new strategies to harness the body’s immune system against malignant cells. Recent advances in this field, including the development of immune checkpoint inhibitors and adoptive cell therapies, have shown promising results in certain subtypes of breast cancer. However, challenges such as variable treatment responses and immune-related adverse events remain. This article explores the recent progress in breast cancer immunotherapy and discusses future directions to optimize its efficacy and broaden its applicability.